A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a commercial stage biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced via our proprietary ProCellEx® plant cell-based protein expression system. We are the first and only company to gain FDA approval of a protein produced through plant cell-based expression in suspension. Our unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. To date, we have successfully developed two commercial products, both of which are enzyme replacement therapies (ERTs): Elfabrio® (pegunigalsidase alfa) for the treatment of adult patients with a confirmed diagnosis of Fabry disease and Elelyso® (taliglucerase alfa) for the treatment of adult patients with Gaucher disease.
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 62M | 53M | 65M | 48M | 38M | 63M |
| Net Income | 5.4M | 2.9M | 8.3M | -15M | -28M | -6.5M |
| EPS | $0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 | $-0.22 |
| Free Cash Flow | -12M | 7.4M | -2.5M | -26M | -12M | -27M |
| ROIC | 20.7% | 9.4% | 18.5% | -85.1% | -21.9% | 4.8% |
| Gross Margin | 57.5% | 54.5% | 64.9% | 58.9% | 57.4% | 82.7% |
| Debt/Equity | 0.00 | 0.00 | 2.05 | -2.65 | -5.30 | -2.04 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | 6.4M | 3.9M | 10M | -13M | -20M | 2.7M |
| Operating Margin | 10.3% | 7.3% | 16.0% | -27.3% | -53.4% | 4.3% |
| ROE | 10.2% | 7.6% | 24.8% | - | - | - |
| Shares Outstanding | 80M | 73M | 92M | 48M | 44M | 30M |
Protalix BioTherapeutics, Inc. passes 3 of 9 quality checks, indicating weak fundamentals.
Protalix BioTherapeutics, Inc. trades at 28.6x trailing earnings, compared to its 15-year median P/E of 20.0x, suggesting it is currently Fair relative to its historical range. The company's 5-year average gross margin is 63.7%. At current prices, the estimated annualized return to fair value is +0.7%.
Protalix BioTherapeutics, Inc. (PLX) has a current P/E ratio of 28.6, compared to its historical median P/E of 20.0. The stock is currently considered Fair based on its historical valuation range.
Protalix BioTherapeutics, Inc. (PLX) has a 5-year average return on invested capital (ROIC) of -14.9%. This is below average and may indicate limited pricing power.
Protalix BioTherapeutics, Inc. (PLX) has a market capitalization of $184M. It is classified as a small-cap stock.
Protalix BioTherapeutics, Inc. (PLX) does not currently pay a regular dividend.
Based on historical P/E analysis, Protalix BioTherapeutics, Inc. (PLX) appears fair. The current P/E of 28.6 is 43% above its historical median of 20.0. The estimated fair value CAGR (P/E method) is -38.3%.
Protalix BioTherapeutics, Inc. (PLX) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Protalix BioTherapeutics, Inc. (PLX) reported annual revenue of $53 million in its most recent fiscal year, based on SEC EDGAR filings.
Protalix BioTherapeutics, Inc. (PLX) has a net profit margin of 5.5%. This is a modest margin.
Protalix BioTherapeutics, Inc. (PLX) generated $7 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Protalix BioTherapeutics, Inc. (PLX) has a debt-to-equity ratio of 0.00. This indicates a conservatively financed balance sheet.
Protalix BioTherapeutics, Inc. (PLX) reported earnings per share (EPS) of $0.04 in its most recent fiscal year.
Protalix BioTherapeutics, Inc. (PLX) has a return on equity (ROE) of 7.6%. This indicates moderate shareholder returns.
Protalix BioTherapeutics, Inc. (PLX) has a 5-year average gross margin of 63.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 16 years of financial data for Protalix BioTherapeutics, Inc. (PLX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Protalix BioTherapeutics, Inc. (PLX) has a book value per share of $0.59, based on its most recent annual SEC filing.